Impact of Clinical and Sociodemographic Factors on Fatigue Among Patients With Substance Use Disorder: A Cohort Study From Norway for The Period 2016-2020

Jørn Henrik Vold (jorn.vold@uib.no)
Universitetet i Bergen Det medisinsk-odontologiske fakultet

Rolf Gjestad
Haukeland University Hospital: Haukeland Universitetssjukehus

Christer F. Aas
Haukeland University Hospital: Haukeland Universitetssjukehus

Fatemeh Chalabianloo
Haukeland University Hospital: Haukeland Universitetssjukehus

Svetlana Skurtveit
FHI: Folkehelseinstituttet

Else-Marie Løberg
Haukeland University Hospital: Haukeland Universitetssjukehus

Kjell Ame Johansson
Haukeland University Hospital: Haukeland Universitetssjukehus

Lars Thore Fadnes
Haukeland University Hospital: Haukeland Universitetssjukehus

Research

Keywords: Substance-related disorders, fatigue, Fatigue Severity Scale, quality of life, comorbidities, illicit drugs, viral human hepatitis, HIV, kidney disease.

DOI: https://doi.org/10.21203/rs.3.rs-80035/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background The impact of clinical and sociodemographic factors on fatigue remains unknown among patients with substance use disorders (SUD). This study aims to evaluate fatigue among patients with SUD using a nine-item fatigue severity scale (FSS-9) and identify the impact that clinical and sociodemographic factors – such as injecting substance use, chronic infectious diseases, liver fibrosis, opioid agonist therapy (OAT), debt difficulties, and housing situation – have on fatigue.

Methods We used data from a cohort of patients with SUD in Norway with annual health assessments surveying FSS-9 and some clinical and sociodemographic factors. A total of 915 FSS-9 measurements were collected from 654 patients during the period 2016-2020. We defined baseline as the first annual health assessment when the health assessments were listed chronologically. Time was defined as months from baseline. We used a linear mixed model to analyse whether the clinical and sociodemographic factors affected the FSS-9 sum score, presented with beta coefficients (β) with 95% confidence intervals (CI).

Results The mean sum score of the FSS-9 was 43 (standard deviation: 16) at baseline. Being female (change in FSS-9 sum score: 4.1, 95 % CI: 1.3-7.0), having debt difficulties (2.9;0.4-5.3), and using benzodiazepines (5.7;3.0-8.4), amphetamine or cocaine (-5.0;-8.0--2.0) affected the FSS-9 sum score. The other clinical and sociodemographic factors did not predict any clinically relevant change in the FSS-9 sum score from baseline to the following health assessments.

Conclusion Patients with SUD suffer from high levels of fatigue. Focusing on closer follow-up of females and reducing debt difficulties and the use of benzodiazepines may mitigate fatigue in the SUD population.

Intro-hcv Study Group Participating Investigators

Bergen: Christer Frode Aas, Vibeke Bråthen Buljovcic, Fatemeh Chalabianloo, Jan Tore Daltveit, Silvia Eiken Alpers, Lars T. Fadnes (principal investigator), Trude Fontenes Eriksen, Per Gundersen, Velinda Hille, Kristin Holmelid Håberg, Kjell Ame Johansson, Rafael Alexander Leiva, Siv-Elin Leirvåg Carlsen, Martine Lepsøy Bonnier, Lennart Lorås, Else-Marie Løberg, Mette Hegland Nordbotn, Cathrine Nygård, Maria Olsvold, Christian Ohldieck, Lillian Sivertsen, Hugo Torjussen, Jørn Henrik Vold, Jan-Magnus Økland

Stavanger: Tone Lise Eielsen, Nancy Laura Ortega Maldonado, Ewa Joanna Wilk

proLAR: Ronny Bjømestad, Ole Jørgen Lygren, Marianne Cook Pierron

Oslo: Olav Dalgard, Håvard Midgard, Svetlana Skurtveit

Bristol: Peter Vickerman

1. Background

Patients with Substance Use Disorders (SUD) suffer from a broad range of health-related difficulties that may contribute to fatigue [1–3]. Fatigue presents itself as a persistent and overwhelming feeling of exhaustion and loss of energy. The condition is mainly associated with chronic diseases and may mitigate treatment adherence and exacerbate comorbid disorders [4, 5]. In SUD populations, a myriad of external factors can interact with fatigue and affect these patients’ general well-being [6–8]. Injecting substance use, internal organ dysfunctions (predominantly kidney and liver diseases), mental disorders, as well as low income, unemployment, and homelessness are some of the external factors that interact with fatigue. Despite this, relatively little attention has been paid to the extent of fatigue and how much various external factors influence fatigue among patients with SUD. Therefore, understanding the key factors affecting fatigue is essential to improve treatment outcomes and adherence in this population.
Fatigue is associated with several sociodemographic and clinical factors. Among patients with the Hepatitis C Virus (HCV) infection, 50–80% have reported fatigue [9], while 33–88% of those with the Human Immunodeficiency Virus (HIV) infection have presented the same symptom [10]. A more uncertain prevalence of fatigue is seen among patients with the Hepatitis B Virus (HBV) [11, 12]. In addition, females, patients with lower educational levels, and those with opioid use disorders undergoing Opioid Agonist Therapy (OAT) with methadone or buprenorphine generally have a greater risk of fatigue [13, 14]. Disentangling the effects of the potential factors influencing fatigue in patients with SUD is essential for individualised treatment and developing clinical guidelines.

Fatigue is a subjective concept, and various definitions and instruments are used in the literature to capture it, which makes interpretations more complicated [15–17]. The nine-item fatigue severity scale (FSS-9) is a well-known questionnaire used to quantify fatigue treatment effects. It shows excellent validity and reliability across various chronic neurological and infectious diseases, such as multiple sclerosis [15], HCV infection [18], stroke [5], and Parkinson's disease [19]. The fact that FSS-9 shows a high consistency across various chronic diseases makes it particularly suitable to estimate fatigue among patients suffering from SUD with complex and challenging comorbidities.

Thus, this prospective cohort study aims to investigate fatigue using the nine-item Fatigue severity scale (FSS-9) among patients with substance use disorders (SUDs) and predict the impact of sociodemographic and clinical factors on FSS-9, including educational level, housing situation, debt difficulties, chronic infectious diseases, injecting substance use, substance use, liver fibrosis, and kidney disease. Moreover, we estimate:

1. using annual health assessments, the FSS-9 sum score and whether and to what extent the sociodemographic and clinical factors impact this score;
2. the impact of sociodemographic and clinical factors on changes in the FSS-9 sum score from the first health assessment to the following annual health assessments;
3. for patients on opioid agonist therapy (OAT) receiving methadone or buprenorphine, the FSS-9 sum score, whether and to what extent the sociodemographic and clinical factors affect the FSS-9 sum score at baseline, and any changes in the FSS-9 sum score from the first health assessment to the following annual health assessments.

2. Methods

2.1. Data source

We used data from a cohort nested to the INTRO-HCV trial on patients with SUD in Bergen and Stavanger, Norway [20]. We collected data from May 2016 to January 2020, and recruited patients on OAT from outpatient clinics in Bergen and Stavanger, as well as patients with various SUDs receiving primary healthcare from the municipality clinics in the city of Bergen.

2.2. Data collections

All included patients were assessed yearly with a health assessment, including FSS-9 measurements, sociodemographic data, and current substance use. Additionally, blood samples and liver fibrosis measurements using transient elastography were conducted. We collected all data in a health register using electronic data collection software (Checkware®) under research nurses’ supervision. All the clinical data, including information regarding OAT, OAT medication, substance use, and possible comorbid clinical conditions, were collected from the electronic medical record.

2.3. Study population

We included 915 FSS-9 measurements from 654 patients in the study period. In total, 225 had follow-up data and conducted the health assessment, including the FSS-9 questionnaire, twice (n=188) or thrice (n=37), providing 487 repeated
measurements. The median interval between the health assessments, including FSS-9 measurements, was 11 months (Interquartile range (IQR): 9 – 14) (Additional File 1).

2.4. Measuring fatigue

We measured fatigue during the last week using FSS-9, including items considering: mental and physical functioning, motivation, carrying out duties, and interference with work, family, or social life. An FSS-9 measurement was completed when all nine items in the questionnaires were entirely conducted during an annual health assessment. The FSS-9 items were answered on a Likert scale – ranging from 1 (no fatigue) to 7 (worst fatigue) – that demonstrates the fatigue level. A high score of FSS-9 items notes a high level of fatigue, while a mean FSS-9 item score greater than 4.0 revealed severe fatigue. The data collection software only allowed valid responses to each question and prompted empty questions before submission to minimise missing data. The FSS-9 was also translated and back-translated from the US-English version into Norwegian by qualified native Norwegian-speaking translators (Additional File 2) [21].

2.5. Measuring liver stiffness and assessing blood samples

We assessed liver stiffness using transient elastography (Fibroscan®) to reveal liver fibrosis and cirrhosis. The elastography was reported as a median score of 10 measurements conducted by research nurses. A liver stiffness above 10 kilopascals (kPa) was defined as liver fibrosis, while a value above 12.5 kPa indicated liver cirrhosis [22]. We also collected blood samples, including hemoglobin, thrombocytes, C - reactive protein, aspartate aminotransferase, estimated glomerular filtration rate, hepatitis B surface antigen (HBsAg), HIV antigen/antibodies, HCV antibodies, and HCV polymerase chain reaction (HCV PCR) during the annual health assessment. Liver stiffness was estimated by calculating the AST to platelet ratio index (APRI) score and using transient elastography (Fibroscan®) (Additional File 3). Moreover, the hematological and biochemical samples were analysed to detect anemia (Hemoglobin), infection or inflammation (C – reactive protein), kidney disease (estimated glomerular filtration rate), liver disease (APRI), or chronic infectious diseases (HIV, HCV, and HBV), which could affect the FSS-9 score. Both elastography and blood samples were examined annually and simultaneously when conducting the annual health assessments. We analysed the blood samples at the Department of Laboratory Medicine, Haukeland University Hospital, Bergen, Norway, and at the Department of Medical Biochemistry and Microbiology, Stavanger University Hospital, Stavanger, Norway (accredited by ISO-standard 15189).

2.6. Definition of study variables, including sociodemographic and clinical factors

We defined baseline for patients as the first annual health assessment that included an FSS-9 measurement when we listed the health assessments chronologically. We dealt with each FSS-9 measurement as a sum score by summarising the value (one to seven) from each item and as a mean score calculated by dividing the sum score by nine (nine items). We defined being on OAT according to whether patients received buprenorphine or methadone (OAT opioids) at baseline. Further, in accordance with the World Health Organization's standards, we calculated the daily dose of received OAT opioids as a ratio between the received dose per day divided by the expected mean dose of OAT opioids (buprenorphine 18 mg, buprenorphine-naloxone 18/4.5 mg or methadone 90 mg) [23]. We categorised educational level into five groups: ‘not completed primary school,’ ‘completed primary school (nine years),’ ‘completed high school (12 years),’ ‘three or fewer years of college or university’ or ‘more than three years of college or university.’ Patients’ housing situations in the 30 days prior to the FSS-9 measurement were classified into two groups: “stable” and “unstable.” The latter category involved patients who had lived on the street, in a homeless shelter, or with family and friends during the past 30 days. Others who had a more permanent residence were classified as having a stable housing situation. Debt difficulties were defined as striving with paying off legal or illegal debt due to a constrained private economy. We set ‘injecting substance use’ as having injected at any time during the past 12 months, whereas frequent substance use was categorised as consuming at least one of the substance groups, including ‘benzodiazepines or z-hypnotics,’ ‘cannabis,’ ‘stimulants (amphetamine or cocaine),’ ‘alcohol,’ and ‘heroin or other illicit opioids’, more than weekly during the 12 months prior to a health assessment. Patients who did not use substances or used them less than weekly during the past 12 months were categorised as having ‘no frequent use
of substance’. Having chronic infectious diseases was defined as detecting HCV PCR (HCV), HBsAg (HBV), or HIV antigen/antibodies (HIV) in the blood samples. For HCV PCR, we used the Helmert contrast in order to classify patients into two groups – transmitted and non-transmitted – and further into two subgroups: whether patients have a low viral load (< 800 000 IU/ml) or high viral load (≥ 800 000 IU/ml). A high virulent HCV infection indicates a high liver inflammation level and a greater likelihood of fatigue [24].

2.7. Statistical analyses

We used Stata/SE 16.0 (StataCorp, TX, USA) for descriptive analysis and IBM SPSS version 26.0 for expectation-maximisation imputation and linear mixed model analyses. The threshold for statistical significance was set to $P < 0.05$ for all analyses unless otherwise stated. In all analyses, we defined time as months from baseline.

We dealt with any missing values concerning sociodemographic and clinical factors – such as educational level, housing situation, debt difficulties, receiving OAT, OAT opioid dose ratio, injecting substance use, substance use, and the results of defined blood samples and transient elastography – as ‘missing at random’ when running expectation-maximisation imputation. We identified missing values in 2.6 % in these factors and all were replaced with estimated values by imputation.

The FSS-9 sum score at baseline was calculated by summarising the nine items’ points. Linear mixed model analyses were used to investigate whether the sociodemographic and clinical factors affected the FSS-9 sum score and to what extent they impacted any changes in the score from baseline to following the health assessments. First, the factor variables were analysed separately as outcome variables as a function of the time (time from baseline). We did not identify substantial significant changes in the sociodemographic and clinical factors between the annual health assessments. Thus, baseline levels were used as stable predictors in the prediction of the level and changes in FSS-9. We specified the linear mixed models as a random intercept fixed slope regression model. The estimator was set to Restricted Maximum Likelihood. To explore whether predictors predicted changes in outcome, the interactions between these factors and time were added to the model. The full information maximum likelihood ensured that all available FSS-9 sum score measurements were used. Additionally, we ran similar analysis models by only including OAT patients using methadone or buprenorphine, respectively. For these analyses, we added the OAT opioid ratio as a predictor. The potential correlations between sociodemographic and clinical factors and fatigue are presented in Additional File 4.

2.8. Ethics approval and consent to participate

The study is reviewed and approved by the Regional Ethical Committee for Health Research West, Norway (REK Vest 2017/51). Each patient provided written informed consent prior to enrolling in the study.

3. Results

3.1. Patients characteristics at baseline

Seventy-one percent of patients were male, and the mean age was 43 years (standard deviation (SD): 11 years) at baseline (Table 1). Six percent had not completed primary school, or 44 % had primary school as their highest educational level. 82 % received OAT, of which 60 % received buprenorphine or buprenorphine-naloxone as an OAT opioid. Further, 13 % had an unstable housing situation in the last 30 days leading up to the FSS-9 measurement. 73 % had used at least one substance weekly during the past 12 months.

3.2.1 FSS-9 sum scores at baseline

The mean sum score for the FSS-9 was 43 (SD: 16), representing a mean score for the FSS-9 items of 4.8 (2.6) (Table 2). A total of 69 % of patients had severe fatigue. The mean FSS-9 sum score was slightly left-skewed (skewness: -0.7) and
tended towards a flattened distribution (kurtosis: 2.4).

### 3.2.2. The sociodemographic and clinical factors’ impact on the FSS-9 sum score at baseline and the factors’ influence on changes in the FSS-9 sum score from baseline to the following annual health assessments

At baseline, we found that the FSS-9 sum score was higher among female (FSS-9 sum score: 4.1, 95% confidence interval: 1.3 to 7.0), patients with debt difficulties (2.9, 0.4 to 5.3) and those using benzodiazepines (5.7, 3.0 to 8.4), whereas the FSS-9 sum score was lower for patients using stimulants frequently (-5.0, -8.0 to -2.0) (Table 3). Further, using benzodiazepines frequently (-0.4, -0.7 to -0.1) and having liver fibrosis or cirrhosis measured by transient elastography (-0.5, -0.8 to -0.1) contributed a small non-clinical significant reduction of the FSS-9 sum score from baseline to the following annual health assessments.

### 3.2.3. The sociodemographic and clinical factors’ impact on changes in the FSS-9 sum score from baseline to the following annual health assessments among patients on OAT

We did not find any differences in the FSS-9 sum score at baseline when comparing patients receiving methadone with patients using buprenorphine as an OAT opioid (Additional Files 5-6). However, among patients receiving methadone as an OAT opioid, we found that those being female (7.3, 2.5 to 12.2), having debt difficulties (4.9, 0.7 to 9.1), using benzodiazepines frequently (6.0, 1.6 to 10.5), and having a high HCV viral load (31.5, 1.5 to 61.5) increased the FSS-9 sum score at baseline. Among patients receiving buprenorphine as an OAT opioid, we found that using alcohol frequently (4.8, 0.2 to 9.3) increased the FSS-9 sum score, whereas using stimulants frequently (-5.0, -9.9 to -0.1) reduced the FSS-9 score at baseline. For both patients who received methadone or buprenorphine as OAT opioids, sociodemographic and clinical factors had no clinically relevant impact on changes in the FSS-9 sum score from baseline to the following annual health assessments.

### 4. Discussion

This study showed that 69% of SUD patients had severe fatigue symptoms. Fatigue was associated with being female, using benzodiazepines frequently, and having debt difficulties. In contrast, less fatigue was seen among patients using stimulant substances such as amphetamines. Comparing OAT patients receiving methadone with those using buprenorphine as an OAT opioid did not reveal any differences in fatigue. However, using benzodiazepines frequently, having debt difficulties, and having a high viral load of HCV were independently related to more fatigue among patients receiving methadone than those using buprenorphine.

In the present study, patients with SUD had a mean fatigue score (4.8) comparable to some of the most severe chronic diseases. In recent studies, patients infected with HIV or HCV, or those coinfected with both of them, had a mean FSS-9 score that ranged from 3.3 to 4.5 [25–27]. Patients with myasthenia gravis have reported a comparable fatigue score of 4.7 [28], and similarly, so have patients who have suffered from a stroke at least six months after the stroke onset (4.8) [29]. One can assume that a high prevalence of underlying mental disorders, extensive polysubstance use, and lower social status could have attributed to the high level of fatigue in the SUD population.

We found that females had higher levels of fatigue than males, mainly when benzodiazepines were used frequently. Recent studies evaluating fatigue in the general population and patients with chronic disorders have demonstrated similar gender differences in fatigue levels [13, 21, 28, 30]. Gender inequalities regarding household responsibilities and caring for the family have generally been highlighted as explanations for females’ fatigue levels [31]. Additionally, females with SUD may be worse off than males in many domains. They may have less financial resources, experience more physical trauma caused by exchanging sex for drugs and money, and face more stigma related to family failures [31]. Moreover, in the general population and among patients with SUDs, females are more likely to use benzodiazepines than males, with a similar tendency found in different countries [2, 32–35]. Females’ higher prevalence of anxiety disorders, sleeping disorders,
and the fact that they are more likely to seek medical care may contribute to more prescriptions of hypnotics and anxiolytics, such as benzodiazepines and z-hypnotics [36–38]. One can believe that these medical, psychological, and social challenges may overall explain the gender gap concerning a higher fatigue level among females in the SUD population.

Our findings reveal that frequent use of benzodiazepines increases fatigue, while frequent use of stimulants decreases fatigue. The impact of these substances on fatigue was expected considering benzodiazepines’ sedative properties and the stimulating effects of amphetamines or cocaine. Nevertheless, the substances’ impact was small, with an average FSS-9 sum score change of plus five points for benzodiazepine use and minus five points for stimulant use on a scale ranging from nine to 63 points. However, the associations between fatigue and substance use in SUD populations are not fully investigated. Benzodiazepine use is overall associated with lower quality of life, self-reported physical health, and more disability than non-benzodiazepine use in the general population [39, 40], which is transferable with the lower fatigue levels shown in the present study. Furthermore, using stimulants, particularly illicit amphetamines, is generally associated with poor mental health and stimulant withdrawal symptoms in the SUD populations [41, 42]. A temporary sense of better self-perceived mental health and fewer withdrawal symptoms may arise when consuming stimulant substances, which contributes to a temporary reduction of fatigue compared to the experience without stimulants. Therefore, FSS-9 scores could have reached a higher level for some stimulant users depending on the use of stimulants before health assessments, the frequency of use, and whether the cases involved underlying mental health conditions or ongoing withdrawal symptoms.

The present study shows no clear associations between fatigue and chronic infectious diseases or kidney disease. For the lack of association between HBV and fatigue among SUD patients, no comparable studies are presented; however, studies comparing patients with HBV in the general population and healthy controls show equivocal results when it comes to fatigue [11, 12]. For patients with HIV or end-stage kidney disease, the low prevalence of HIV and a mean renal function within the normal range could explain why no associations with fatigue were detected. Furthermore, we were surprised that patients with HCV infections did not demonstrate a higher fatigue level. However, the large extent of polysubstance use in the present population (75%) could have temporarily displaced the HCV infection’s impact on fatigue.

We did not find any fatigue level differences when comparing patients using methadone with those using buprenorphine as an OAT opioid. However, we found that some sociodemographic and clinical factors affected fatigue among methadone users. Methadone is a full opioid agonist associated with more euphoria and analgesia than the partial opioid agonist buprenorphine [43]. In a quantitative study evaluating patients’ experience of using methadone and buprenorphine on OAT, over-sedation has been particularly pointed out as a negative physical effect of methadone in some cases [44]. Therefore, there was some surprise that in the present study patients on methadone did not reach a higher fatigue level compared to patients using buprenorphine. Notably, according to Norwegian OAT guidelines, buprenorphine is the first drug of choice when entering OAT [45]. In line with the Norwegian recommendation, buprenorphine has been increasingly used in OAT during recent years [46]. Our results could indicate a high degree of similarity between methadone and buprenorphine users in terms of the degree of opioid dependence and sociodemographic and clinical factors, including substance use, which could contribute to the inability to identify fatigue differences.

5. Strengths And Limitations

This study has several strengths. We have included 654 patients with SUD that usually are difficult to reach in health care. Of those, 225 patients were followed up by two or three annual health assessments, making longitudinal analyses possible. This study does, however, have some limitations. First, the patients were mainly recruited from outpatient clinics receiving OAT. The majority had opioid dependence, although this was often combined with other dependencies, which could affect the generalisability of our results to other SUD populations. Second, we had a prospective follow-up of only a third of those patients recruited at baseline. This also causes weakness in our results and makes it necessary to carefully interpret the
longitudinal analyses. Third, due to clinical challenges, including systematic and patient delays, the annual health assessments were not precisely conducted one year after the previous health assessment. This may affect the interpretation of the predicted fatigue level changes from baseline.

6. Conclusion

The present study shows that patients with SUD suffer from substantial fatigue symptoms. We saw more fatigue symptoms among females, those who used benzodiazepines, and those with debt difficulties, while those using stimulants were slightly less fatigued. We did not identify any direct differences between the OAT medications methadone and buprenorphine. Still, methadone seemed to be an effect modifier potentiating more sociodemographic and clinical factors than buprenorphine. In conclusion, focusing on a closer follow-up of females, reducing debt difficulties, and helping patients minimise the extensive use of benzodiazepines may mitigate fatigue in the SUD population.

7. Abbreviations

APRI: Aspartate transaminase to platelet ratio index
CI: Confidence interval
FSS-9: Nine-item Fatigue Severity Scale
HBsAg: Hepatitis B surface antigen
HBV: Hepatitis B Virus
HCV: Hepatitis C Virus
HCV PCR: HCV polymerase chain reaction
HIV: Human Immunodeficiency Virus
IQR: Interquartile range
OAT: Opioid Agonist Therapy
SUD: Substance use disorder
SD: Standard deviation

8. Declarations

Ethics approval and consent to participate

The study has been reviewed and approved by the Regional Ethical Committee for Health Research (REC) West, Norway (reference number: 2017/51/REK Vest, dated 29.03.2017/20.04.2017). Each patient provided written informed consent prior to enrolling in the study.

Consent for publication

Participants have consented for publication

Availability of data and material
No additional data are available due to data protection requirements.

**Competing interests**

Not applicable

**Funding**

This work was supported by The Norwegian Research Council (BEHANDLING, contract no 269855) and the Western Norway Regional Health Authority («Åpen prosjektstøtte») with the Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway as responsible institution. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Two of the authors are funded from the research grant BEHANDLING related to the project INTRO-HCV from the Norwegian Research Council. The other authors are funded by their respective affiliations.

**Authors’ contributions**

Jørn Henrik Vold and Rolf Gjestad have led the study design, analysis, and article preparation. Christer Aas, Fatemeh Chalabianloo, Svetlana Skurtveit, Else-Marie Løberg, Kjell Arne Johansson, and Lars Thore Fadnes have contributed by leading the study design, analysis, and article preparation. All authors have read and approved the final article.

**Acknowledgements**

We thank the devoted clinical staff for their enthusiasm during the planning of the project. We also thank Nina Elisabeth Eltvik and Christer Kleppe for their valuable help and input during the planning and preparation phases.

**Authors’ information**

Jørn Henrik Vold, MD, Department of Addiction Medicine, Haukeland University Hospital, and Department of Global Public Health and Primary Care, University of Bergen. Mailing address: Department of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, N-5021 Bergen, Norway. E-mail: jorn.vold@uib.no.

9. References

1. Lugoboni F, Mirijello A, Faccini M, Casari R, Cossari A, Musi G, Bissoli G, Quaglio G, Addolorato G: Quality of life in a cohort of high-dose benzodiazepine dependent patients. *Drug Alcohol Depend* 2014, **142**:105-109.

2. Votaw VR, Geyer R, Rieselbach MM, McHugh RK: The epidemiology of benzodiazepine misuse: A systematic review. *Drug Alcohol Depend* 2019, **200**:95-114.

3. Morris L, Stander J, Ebrahim W, Eksteen S, Meaden OA, Ras A, Wessels A: Effect of exercise versus cognitive behavioural therapy or no intervention on anxiety, depression, fitness and quality of life in adults with previous methamphetamine dependency: a systematic review. *Addict Sci Clin Pract* 2018, **13**(1):4.

4. Claborn KR, Meier E, Miller MB, Leffingwell TR: A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. *Psychol Health Med* 2015, **20**(3):255-265.

5. Ozyemisci-Taskiran O, Batur EB, Yuksel S, Cengiz M, Karatas GK: Validity and reliability of fatigue severity scale in stroke. *Top* 2019, **26**(2):122-127.

6. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K et al: Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health* 2017, **5**(12):e1192-e1207.
7. Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, Wong WWL, Grootendorst P, Krahn MD: Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis. J Viral Hepat 2018, 25(5):502-513.

8. Zacks SL, Fried MW: Hepatitis B and C and renal failure. Infect Dis Clin North Am 2001, 15(3):877-899.

9. Friedberg F, Tintle N, Clark J, Bromet EJ: Prolonged fatigue in Ukraine and the United States: Prevalence and risk factors. Fatigue 2015, 3(1):33-46.

10. Jong E, Oudhoff LA, Epskamp C, Wagener MN, van Duijn M, Fischer S, van Gorp EC: Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. Aids 2010, 24(10):1387-1405.

11. Evon DM, Wahed AS, Johnson G, Khalili M, Lisker-Melman M, Fontana RJ, Sarkar S, Reeve BB, Hoofnagle JH: Fatigue in patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN). Dig Dis Sci 2016, 61(4):1186-1196.

12. Saffari M, Pakpour AH, Al Zaben F, Koenig HG: Is there an association between Health Related Quality of Life, socio-demographic status and Fatigue in Patients with Chronic Hepatitis B? Acta Gastroenterol Belg 2017, 80(2):229-236.

13. Galland-Decker C, Marques-Vidal P, Vollenweider P: Prevalence and factors associated with fatigue in the Lausanne middle-aged population: a population-based, cross-sectional survey. BMJ Open 2019, 9(8):e027070.

14. Maglione MA, Raaen L, Chen C, Azhar G, Shahidinia N, Shen M, Maksabedian E, Shanman RM, Newberry S, Hempel S: Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review. J Subst Abuse Treat 2018, 89:28-51.

15. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46(10):1121-1123.

16. S. F, S. T, M. I, K. Y, H. K, Y. W: Development and Validation of a New Fatigue Scale for Fatigued Subjects With and Without Chronic Fatigue Syndrome. Watanabe Y, Evengård B, Natelson BH, Jason LA, Kuratsune H (eds) Fatigue Science for Human Health Springer, Tokyo 2008.

17. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP: Development of a fatigue scale. J Psychosom Res 1993, 37(2):147-153.

18. Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J: Validation of the Fatigue Severity Scale in chronic hepatitis C. Health & Quality of Life Outcomes 2014, 12:90.

19. Siciliano M, Chiorri C, De Micco R, Russo A, Tedeschi G, Trojano L, Tessitore A: Fatigue in Parkinson's disease: Italian validation of the Parkinson Fatigue Scale and the Fatigue Severity Scale using a Rasch analysis approach. Parkinsonism Relat Disord 2019, 65:105-110.

20. Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgard O, Vickerman P et al: Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC infectious diseases 2019, 19(1):943.

21. Lerdal A, Wahl A, Rustøen T, Hanestad BR, Moum T: Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand J Public Health 2005, 33(2):123-130.

22. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Lédinghen V: Diagnosis of cirrhosis by transient elastography ( FibroScan): a prospective study. Gut 2006, 55(3):403-408.

23. Arpadi S, Fawzy A, Aldrovandi GM, Kankasa C, Sinkala M, Mwiya M, Thea DM, Kuhn L: Growth faltering due to breastfeeding cessation in uninfected children born to HIV-infected mothers in Zambia. The American journal of clinical nutrition 2009, 90(2):344-353.

24. Shahid M, Idrees M, Nasir B, Raja AJ, Raza SM, Amin I, Rasul A, Tayyab GU: Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients. Eur J Gastroenterol Hepatol 2014, 26(7):788-794.
25. Kleefeld F, Heller S, Ingiliz P, Jessen H, Petersen A, Kopp U, Kraft A, Hahn K: Interferon-free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health. *J Neurovirol* 2018, **24**(5):557-569.

26. Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L: Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. *BMC Infectious Diseases* 2014, **14**:465.

27. Lee KA, Jong S, Gay CL: Fatigue management for adults living with HIV: A randomized controlled pilot study. *Res Nurs Health* 2020, **43**(1):56-67.

28. Alekseeva TM, Gavrilov YV, Kreis OA, Valko PO, Weber KP, Valko Y: Fatigue in patients with myasthenia gravis. *J Neurol* 2018, **265**(10):2312-2321.

29. Naess H, Lunde L, Brogger J: The effects of fatigue, pain, and depression on quality of life in ischemic stroke patients: the Bergen Stroke Study. *Vasc Health Risk Manag* 2012, **8**:407-413.

30. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH: Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. *Journal of hepatology* 2012, **57**(5):946-952.

31. Arpa S: Women who use drugs: Issues, needs, responses, challenges and implications for policy and practice. In: https://www.emcdda.europa.eu/system/files/attachments/6235/EuropeanResponsesGuide2017_BackgroundPaper-Women-who-use-drugs.pdf: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2017.

32. Skurtveit S, Sakshaug S, Hjellvik V, Berg C, Handal M: Use of addictive drugs in Norway 2005-2013 (Norsk: Bruk av vanedannende legemidler i Norge 2005-2013). In: https://www.fhi.no/globalassets/dokumenterfiler/rapport/2014/bruk-av-vanedannende-legemidler-pdf.pdf: Norwegian Institute of Public Health; 2014, June 2014.

33. Airagnes G, Lemogne C, Renuy A, Goldberg M, Hoertel N, Roquelaure Y, Limosin F, Zins M: Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTATENCES cohort. *BMC Public Health* 2019, **19**(1):566.

34. Petitjean S, Ladewig D, Meier CR, Armein R, Wiesbeck GA: Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. *Int Clin Psychopharmacol* 2007, **22**(5):292-298.

35. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL: Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013. *Am J Public Health* 2016, **106**(4):686-688.

36. McLean CP, Asnaani A, Litz BT, Hofmann SG: Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. *J Psychiatr Res* 2011, **45**(8):1027-1035.

37. Krishnan V, Collop NA: Gender differences in sleep disorders. *Curr Opin Pulm Med* 2006, **12**(6):383-389.

38. Wang Y, Hunt K, Nazareth I, Freemantle N, Petersen I: Do men consult less than women? An analysis of routinely collected UK general practice data. *BMJ Open* 2013, **3**(8):e003320.

39. Abrahamsson T, Hakansson A: Nonmedical prescription drug use (NMPDU) in the Swedish general population—correlates of analgesic and sedative use. *Subst Use Misuse* 2015, **50**(2):148-155.

40. Ford JA, Hinojosa MS, Nicholson HL: Disability status and prescription drug misuse among U.S. adults. *Addict Behav* 2018, **85**:64-69.

41. McKetin R, Leung J, Stockings E, Huo Y, Foulds J, Lappin JM, Cumming C, Arunogiri S, Young JT, Sara G et al: Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. *EClinicalMedicine* 2019, **16**:81-97.

42. Pennay AE, Lee NK: Putting the call out for more research: the poor evidence base for treating methamphetamine withdrawal. *Drug Alcohol Rev* 2011, **30**(2):216-222.

43. Whelan PJ, Remski K: Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. *J Neurosci Rural Pract* 2012, **3**(1):45-50.
44. Gryczynski J, Jaffe JH, Schwartz RP, Dušek KA, Gugsa N, Monroe CL, O'Grady KE, Olsen YK, Mitchell SG: *Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system*. *Am J Addict* 2013, 22(3):285-291.

45. The Norwegian guidelines for opioid agonist therapy. In., vol. ISBN: 978-82-8081-155-4. [https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/100/IS-1701-Legemiddelassistert-rehabilitering-ved-opioidavhengighet.pdf](https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/100/IS-1701-Legemiddelassistert-rehabilitering-ved-opioidavhengighet.pdf): The Norwegian Directorate of Health; 2010, August 2010.

46. Vold JH, Skurtveit S, Aas C, Johansson KA, Fadnes LT: *Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013-2017): a prospective cohort study*. *BMC Health Serv Res* 2020, 20(1):668.

**Tables**
Table 1
Sociodemographic and clinical characteristics at baseline for all patients and for patients with more than one annual health assessment

|                      | All patients (N = 654) | Patients with > 1 health assessment (N = 225) |
|----------------------|-------------------------|---------------------------------------------|
| **Age (years), n (%)** |                        |                                             |
| 18–29                | 81 (12)                 | 23 (10)                                    |
| 30–39                | 185 (28)                | 63 (28)                                    |
| 40–49                | 205 (31)                | 75 (33)                                    |
| 50–59                | 148 (23)                | 53 (24)                                    |
| ≥ 60                 | 35 (5)                  | 11 (5)                                     |
| **Mean (SD)**        | 43 (11)                 | 44 (10)                                    |
| **Gender, n (%)**    |                        |                                             |
| Male                 | 461 (71)                | 170 (76)                                   |
| Female               | 193 (29)                | 55 (24)                                    |
| **Highest educational level, n (%)** |              |                                             |
| Not completed primary school | 40 (6) | 15 (7)                                    |
| Completed primary school (9 years) | 286 (44) | 105 (47)                                 |
| Completed high school (12 years) | 259 (40) | 81 (36)                                   |
| ≤ 3 years of college or university | 57 (9) | 20 (9)                                    |
| > 3 years of college or university | 12 (2) | 4 (2)                                     |
| **Receiving opioid agonist therapy, n (%)** |          |                                             |
| 537 (82)             | 205 (91)                |                                             |
| **OAT opioid (%)**   |                        |                                             |
| Methadone            | 209 (39)                | 96 (43)                                    |
| Buprenorphine/Buprenorphine-naloxone | 321 (60) | 107 (48)                                  |
| **OAT opioid dose ratio (median (IQR))**<sup>1)</sup> |          |                                             |
| 0.9 (0.8–1.1)        | 1.0 (0.9–1.1)           |                                             |
| **Housing situation the past 30 days, n (%)** |          |                                             |

FSS-9: Nine-item Fatigue Severity Scale (Likert scale); HCV: Hepatitis C virus; HBsAg: hepatitis B surface antigen; IQR: Interquartile range; OAT: opioid agonist therapy; SD: Standard deviation.

<sup>1)</sup> OAT opioid ratio is a ratio between the received dose of OAT opioids per day and the expected median daily dose (18 mg buprenorphine or 18/4.5 mg buprenorphine-naloxone or 90 mg methadone). A ratio on 1.0 indicates that patients received an expected dose daily; <sup>3)</sup> A stable housing situation was defined as having owned or rented housing situation or being imprisoned; <sup>4)</sup> Unstable housing situation was defined as living in a homeless shelter, with family or friends, or on the street; <sup>5)</sup> Frequent substance use was defined as using substance at least weekly during the past 12 months.

The table displays the sociodemographic and clinical characteristics at baseline for the included patients, and for patients with two or more health assessment, including FSS-9 measurement during the study period.
All patients (N = 654) | Patients with >1 health assessment (N = 225)
--- | ---
Stable<sup>3)</sup> | 569 (87) | 203 (90)
Unstable<sup>4)</sup> | 85 (13) | 22 (10)

**Injected substances the past 12 months, n (%)**

| Substance | All patients | Patients with >1 health assessment |
|-----------|-------------|-------------------------------|
| Alcohol   | 338 (56)    | 116 (52)                      |
| Benzodiazepines | 238 (39) | 87 (39)                   |
| Cannabis  | 313 (52)    | 124 (55)                      |
| Opioids   | 97 (16)     | 27 (12)                       |
| Stimulants (amphetamines and cocaine) | 176 (29) | 60 (27)                     |

**Frequent substance use the past 12 months, n (%)<sup>5)</sup>**

| Substance | All patients | Patients with >1 health assessment |
|-----------|-------------|-------------------------------|
| Alcohol   | 154 (26)    | 56 (25)                       |
| Benzodiazepines | 238 (39) | 87 (39)                   |
| Cannabis  | 313 (52)    | 124 (55)                      |
| Opioids   | 97 (16)     | 27 (12)                       |
| Stimulants (amphetamines and cocaine) | 176 (29) | 60 (27)                     |
| Chronic infectious diseases, n (%)<sup>1)</sup><sup>3)</sup><sup>4)</sup><sup>5)</sup>

| Disease | All patients | Patients with >1 health assessment |
|---------|-------------|-------------------------------|
| Hepatitis C virus infection | 315 (48) | 184 (82) |
| Low virulent (< 800 000 IE/ml) | 168 (25) | 92 (41) |
| High virulent (≥ 800 000 IE/ml) | 147 (22) | 92 (41) |
| Hepatitis B virus infection | 5 (0) | < 5 (< 1) |
| Human immunodeficiency virus | < 5 (< 1) | < 5 (< 1) |

**Hematological and biochemical samples, median (IQR)**

| Sample | All patients | Patients with >1 health assessment |
|--------|-------------|-------------------------------|
| Hemoglobin (g/dl) | 14 (13–15) | 14 (13–15) |
| Estimated glomerulus filtration rate (ml/min/1.73 m<sup>2</sup>) | 104 (89–122) | 105 (91–124) |
| C-reactive protein (mg/L) | 4 (1–9) | 3 (1–8) |
| Aspartate transaminase (U/L) | 31 (23–50) | 40 (30–65) |
| Liver stiffness, median (IQR) | 5 (4–7) | 6 (5–8) |
| Aspartate transaminase to platelets ratio index | 0.3 (0.2–0.6) | 0.4 (0.3–0.8) |

FSS-9: Nine-item Fatigue Severity Scale (Likert scale); HCV: Hepatitis C virus; HBsAg: hepatitis B surface antigen; IQR: Interquartile range; OAT: opioid agonist therapy; SD: Standard deviation.

<sup>1)</sup> OAT opioid ratio is a ratio between the received dose of OAT opioids per day and the expected median daily dose (18 mg buprenorphine or 18/4.5 mg buprenorphine-naloxone or 90 mg methadone). A ratio on 1.0 indicates that patients received an expected dose daily; <sup>3)</sup> A stable housing situation was defined as having owned or rented housing situation or being imprisoned; <sup>4)</sup> Unstable housing situation was defined as living in a homeless shelter, with family or friends, or on the street; <sup>5)</sup> Frequent substance use was defined as using substance at least weekly during the past 12 months.

The table displays the sociodemographic and clinical characteristics at baseline for the included patients, and for patients with two or more health assessment, including FSS-9 measurement during the study period.
### Table 2
Mean (Standard deviation (SD)) item scores for single items on FSS-9 at baseline and follow-up

| Item                                                                 | Baseline (N = 654) | Follow-up (N = 225) |
|----------------------------------------------------------------------|--------------------|---------------------|
| **FSS-9**                                                            |                    |                     |
| I1: My motivation is lower when I am fatigued                       | 5.4 (2.0)          | 5.6 (2.0)           |
| I2: Exercise brings on my fatigue                                    | 4.7 (2.1)          | 5.0 (2.1)           |
| I3: I am easily fatigued                                             | 4.5 (2.1)          | 4.8 (2.1)           |
| I4: Fatigue interferes with my physical functioning                 | 4.9 (2.1)          | 5.6 (2.0)           |
| I5: Fatigue causes frequent problems for me                          | 4.4 (2.2)          | 4.5 (2.2)           |
| I6: My fatigue prevents sustained physical functioning              | 4.6 (2.2)          | 4.4 (2.2)           |
| I7: Fatigue interferes with carrying out certain duties and responsibilities | 5.0 (2.1) | 5.0 (2.1) |
| I8: Fatigue is among my three most disabling symptoms               | 4.6 (2.3)          | 4.8 (2.3)           |
| I9: Fatigue interferes with my work, family, or social life         | 4.9 (2.2)          | 4.6 (2.3)           |
| Mean score of all items                                             | 4.8 (1.8)          | 4.9 (1.7)           |
| Sum score of all items                                              | 43.2 (15.9)        | 43.8 (15.2)         |

Follow-up: FSS-9 score on the last health assessment during the study period among patients with two or more annual health assessments; FSS-9: Nine-item Fatigue Severity Scale (Likert scale); I: Item; SD: Standard Deviation.
Table 3  
Linear mixed model of fatigue (FSS-9) adjusted for sociodemographic and clinical factors (N = 654)

| Fixed effects                  | Effect estimate | Time trend (per month) |
|-------------------------------|-----------------|------------------------|
|                               | Estimate (95% CI) | Slope (95% CI)         |
| **FSS-9 sum score**           | 42 (26–58)       | 0.3 (-1.9–2.5)         |
| **Female**                    | 4.1 (1.3–7.0)    | 0.0 (-0.4–0.3)         |
| **Age per 10 years**          | 0.2 (-1.0–1.4)   | 0.0 (-0.2–0.1)         |
| **Educational level**         | -1.1 (-2.6–0.3)  | 0.0 (-0.2–0.1)         |
| **Unstable housing situation**| 0.0 (-3.7–3.7)   | 0.2 (-0.3–0.7)         |
| **Debt difficulties**         | 2.9 (0.4–5.3)    | 0.0 (-0.3–0.3)         |
| **Injecting substance use**   | -0.1 (-2.9–2.7)  | -0.1 (-0.4–0.3)        |

**Frequent use of substances**

|                          | Effect estimate | Time trend (per month) |
|--------------------------|-----------------|------------------------|
| **Benzodiazepines**      | 5.7 (3.0–8.4)   | -0.4 (-0.7 – -0.1)     |
| **Alcohol**              | 1.8 (-1.1–4.6)  | 0.0 (-0.3–0.4)         |
| **Cannabis**             | 1.2 (-1.4–3.8)  | 0.2 (-0.1–0.4)         |
| **Opioids**              | 3.3 (-0.3–6.9)  | -0.4 (-0.9–0.1)        |
| **Stimulants**           | -5.0 (-8.0–-2.0) | 0.2 (-0.2–0.5)         |

**Chronic infectious diseases**

|                          | Effect estimate | Time trend (per month) |
|--------------------------|-----------------|------------------------|
| **Hepatitis B virus infection** | 3.3 (-10.4–16.9) | -0.2 (-1.4–1.0)       |
| **Hepatitis C virus infection** | 3.0 (-5.4–11.4)  | -0.1 (-1.6–1.7)       |
| - Detected               | -0.4 (-10.3–10.9) | -0.6 (-1.4–0.2)       |
| - Low vs. high viral load|                 |                       |
| **HIV**                  | -0.1 (-15.3–15.5) | 1.1 (-0.6–2.7)        |

APRI: Aspartate transaminase to platelet ratio index; CI: Confidence interval; CRP: C-reactive protein; FSS-9: Nine-item Fatigue Severity Scale; eGFR: estimated glomerular filtration rate; HIV: Human Immunodeficiency virus; kPa: Kilopascal; OAT: Opioid Agonist Therapy.

1) Age per 10 years was centred according to mean age (43 years) in the study population at baseline. 2) Included amphetamine or cocaine use. The educational level: highest level of education was coded 0–4 with 4 as the highest educational level. Unstable housing situation: living on the street, homeless shelter, or with family and friends at any time during the past 30 days prior to the health assessment. Debt difficulties: struggling with repaying current illegal and legal debt. Injecting substance use: Having injected substance during the past 12 months prior to the health assessment. Frequent use of substances: at least weekly during the past 12 months prior to the health assessment. Viral load of HCV: From -0.5 to 0.5, where the range ≥ -0.5 to < 0 represents the low viral load (HCV PCR < 800 000 IE/ml), and the range ≤ 0.5 to >0 identifies the high viral load (HCV PCR ≥ 800 000 IE/ml). Zero (0) defined patients without HCV infection.

The table displays a linear mixed model analysis (Restricted Maximum Likelihood regression) evaluating sociodemographic and clinical factors’ (predictors) impact on the FSS-9 sum score at baseline and the predictors’ impact on changes in the FSS-9 sum score (time trend) per month from baseline.
### Fixed effects

| Liver stiffness | |
|----------------|---|
| Transient elastography per 10 kPa | 1.2 (-1.6–4.0) |
| APRI score per 1 unit | 0.5 (-0.6–1.5) |

### Hematologic and biochemical blood samples (continuous variables)

| Hematologic and biochemical blood samples | |
|-------------------------------------------|---|
| Hemoglobin per 1 unit (g/dL) | -0.3 (-1.1–0.6) |
| eGFR per 30 units (ml/min/1.73 m^2) | 0.0 (-2.0–0.9) |
| CRP per 10 units (ml/L) | -0.1 (-0.6–0.7) |

APRI: Aspartate transaminase to platelet ratio index; CI: Confidence interval; CRP: C-reactive protein; FSS-9: Nine-item Fatigue Severity Scale; eGFR: estimated glomerular filtration rate; HIV: Human Immunodeficiency virus; kPa: Kilopascal; OAT: Opioid Agonist Therapy.

1) Age per 10 years was centred according to mean age (43 years) in the study population at baseline. 2) Included amphetamine or cocaine use. The educational level: highest level of education was coded 0–4 with 4 as the highest educational level. Unstable housing situation: living on the street, homeless shelter, or with family and friends at any time during the past 30 days prior to the health assessment. Debt difficulties: struggling with repaying current illegal and legal debt. Injecting substance use: Having injected substance during the past 12 months prior to the health assessment. Frequent use of substances: at least weekly during the past 12 months prior to the health assessment. Viral load of HCV: From −0.5 to 0.5, where the range ≥ −0.5 to < 0 represents the low viral load (HCV PCR < 800 000 IE/ml), and the range ≤ 0.5 to > 0 identifies the high viral load (HCV PCR ≥ 800 000 IE/ml). Zero (0) defined patients without HCV infection.

The table displays a linear mixed model analysis (Restricted Maximum Likelihood regression) evaluating sociodemographic and clinical factors’ (predictors) impact on the FSS-9 sum score at baseline and the predictors’ impact on changes in the FSS-9 sum score (time trend) per month from baseline.